Gate Bioscience周一表示，已扩大与礼来（Eli Lilly）的研究和许可协议，以开发针对致病蛋白质的疗法，该交易价值可能超过8.7亿美元。
Gate Bioscience said on Monday it expanded a research and licensing agreement with Eli Lilly to develop treatments targeting disease-causing proteins, in a deal potentially worth more than $870 million.